|
ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry.
Combining cost-effective resources and productivity of Asia along with unmatched regulatory know-how, ScinoPharm is uniquely positioned to serve global pharmaceutical R&D and manufacturing needs at any level and for any company in this sector.
Timely Development and Production of High Quality API's
ScinoPharm's capable research and |
 |
development teams, located in both Taiwan and China, in conjunction with its FDA approved state-of-the art cGMP facilities in Taiwan, can assure on-time development of non-infringing patent processes and timely delivery of high quality, price competitive API's to ScinoPharm's customers.
The Company has twelve manufacturing areas (consist of a table of 16 production lines) ranging from kilogram to multi-ton capacities. Several lines are specially equipped to handle high-potency products such as hormones, cytotoxic agents and drug substances for injectable formulations. The company is experienced in preparing and submitting Drug Master Files (DMF) with US and European regulatory agencies. ScinoPharm routinely provides its customers with reference standards and complimentary transfer of validated |
|
analytical methods.
All administrative, support and control functions are monitored and tracked by SAP's Enterprise Resource Planning (ERP) automated system designed specifically for stand-alone API facilities.
Intensive Customer Orientation and Project Management Focus
ScinoPharm Taiwan can provide the speed and flexibility that pharmaceutical companies require when selecting a partner to assist in developing clinical material. ScinoPharm utilizes a matrix research organization using a dedicated project team that emphasizes frequent and timely communications with its customers. Using e-mail and telephone/videoconferencing, ScinoPharm can effectively become an integral part of its customers' in-house development team. |
|
|
